Cargando…

An mRNA processing pathway suppresses metastasis by governing translational control from the nucleus

Cancer cells often co-opt post-transcriptional regulatory mechanisms to achieve pathologic expression of gene networks that drive metastasis. Translational control is a major regulatory hub in oncogenesis; however, its effects on cancer progression remain poorly understood. Here, to address this, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Navickas, Albertas, Asgharian, Hosseinali, Winkler, Juliane, Fish, Lisa, Garcia, Kristle, Markett, Daniel, Dodel, Martin, Culbertson, Bruce, Miglani, Sohit, Joshi, Tanvi, Yin, Keyi, Nguyen, Phi, Zhang, Steven, Stevers, Nicholas, Hwang, Hun-Way, Mardakheh, Faraz, Goga, Andrei, Goodarzi, Hani
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10264242/
https://www.ncbi.nlm.nih.gov/pubmed/37156909
http://dx.doi.org/10.1038/s41556-023-01141-9
Descripción
Sumario:Cancer cells often co-opt post-transcriptional regulatory mechanisms to achieve pathologic expression of gene networks that drive metastasis. Translational control is a major regulatory hub in oncogenesis; however, its effects on cancer progression remain poorly understood. Here, to address this, we used ribosome profiling to compare genome-wide translation efficiencies of poorly and highly metastatic breast cancer cells and patient-derived xenografts. We developed dedicated regression-based methods to analyse ribosome profiling and alternative polyadenylation data, and identified heterogeneous nuclear ribonucleoprotein C (HNRNPC) as a translational controller of a specific mRNA regulon. We found that HNRNPC is downregulated in highly metastatic cells, which causes HNRNPC-bound mRNAs to undergo 3′ untranslated region lengthening and, subsequently, translational repression. We showed that modulating HNRNPC expression impacts the metastatic capacity of breast cancer cells in xenograft mouse models. In addition, the reduced expression of HNRNPC and its regulon is associated with the worse prognosis in breast cancer patient cohorts.